Pantoprazole causes Higher Rate of estimated GFR Decline compared to Placebo Dr. Kamal Kant Kohli9 Nov 2022 11:00 AM ISTCANADA: Compared to placebo, pantoprazole caused a faster rate of eGFR reduction. According to a study published in the American Society of...
Empagliflozin reduces risk of disease progression and death in high-risk CKD patients: NEJM Medha Baranwal7 Nov 2022 10:30 AM ISTUK: Empagliflozin therapy in patients with chronic kidney disease (CKD) lowers the risk of disease progression or death from cardiovascular causes in...
Long term exposure to air pollution increases risk of developing CKD Dr. Kamal Kant Kohli6 Nov 2022 7:00 PM ISTChronic kidney disease (CKD) is a global disease burden related to high rates of incidence and mortality. It manifests as progressive and...
Dapagliflozin effective from clinical standpoint as well as cost standpoint for CKD patients Dr. Kamal Kant Kohli5 Nov 2022 9:30 AM ISTThe burden of chronic kidney disease (CKD) to both healthcare systems and patients is considerable. Dapagliflozin, a sodium-glucose cotransporter-2...
Long-term exposure to air pollution can heighten kidney disease risk Isra Zaman5 Nov 2022 9:00 AM ISTAmong adults with normal kidney function, exposure to higher concentrations of components of air pollution was linked with higher risks of later...
Medical Bulletin 3/November/2022 Isra Zaman3 Nov 2022 11:26 AM ISTHere are the top medical news for the day:ACC, AHA guideline on the diagnosis and management of aortic diseaseThe aorta is the largest artery in the...
Dapagliflozin clinically and cost effective in patients with chronic kidney disease: DAPA-CKD trial Isra Zaman3 Nov 2022 9:15 AM IST A recent analysis in CJASN indicates that in patients eligible for the DAPA-CKD trial, dapagliflozin is not only effective from a clinical...
Anemia and low estimated GFR risk factors for chronic kidney disease patients Dr.Niharika Harsha B27 Oct 2022 8:00 PM ISTNew research found that severe anemia, low iron levels, and low estimated glomerular filtration rates are the risk factors for chronic kidney disease...
AstraZeneca Gets CDSCO panel nod to Import, Market Anti-Diabetic Dapagliflozin for Additional Indication Dr. Divya Colin23 Oct 2022 11:30 AM ISTNew Delhi: Pharmaceutical major AstraZeneca has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard...
Finerenone improves cardiorenal outcomes among patients of diabetes with CKD: The FIDELITY Trial Dr. Kamal Kant Kohli21 Oct 2022 10:30 AM ISTU.S.A.: A trial that was recently published in the Journal of the American College of Cardiology reported that finerenone, a selective, nonsteroidal...
Clinicopathological Study of Chronic Kidney Disease of Unknown Etiology in Odisha Dr. Nandita Mohan18 Oct 2022 9:00 AM ISTChronic kidney disease (CKD) is a global burden and commonly characterized by traditional risk factors like diabetes, hypertension,...
COVID-19 Drug paxlovid may have interaction with commonly prescribed heart medications Dr. Kamal Kant Kohli14 Oct 2022 10:00 AM ISTJACC study points to various drug interactions of COVID drug nirmatrelvir-ritonavir (sold under Paxlovid) with various heart medications
